文献速递妇科生殖医学

卵巢子宫内膜异位囊肿乙醇硬化治疗后复发风险因素与安全性结局

Risk Factors for Recurrence and Safety Outcomes After Ethanol Sclerotherapy for Ovarian Endometriomas.
PubMed 文献 · J Minim Invasive Gynecol · 2026-10-04

这项回顾性队列研究纳入91例18-45岁接受经阴道超声引导乙醇硬化治疗(EST)的卵巢子宫内膜异位囊肿患者,评估复发/持续存在及相关因素。88例可评估患者中25.0%出现复发/持续存在,12个月和24个月累积估计分别为22.3%和29.1%;较高BMI与复发/持续存在独立相关(多变量HR 1.20,95%CI 1.10-1.32,P<0.001)。技术成功率97.4%,围手术期并发症8.8%,无Clavien-Dindo IIIb-V级并发症,AMH在1个月和6个月出现小幅下降。

要点

  • EST技术成功率高(97.4%),无严重并发症,但复发/持续存在仍具临床意义。
  • 较高BMI是复发/持续存在的独立相关因素,多变量HR 1.20(95%CI 1.10-1.32)。
  • 术后AMH小幅下降,1个月中位下降0.16 ng/mL,6个月下降0.12 ng/mL。

核心结论

  • 在这组经过仔细选择的队列中,EST技术成功率高,但复发/持续存在仍具临床意义。
  • 较高BMI与复发/持续存在在主要和敏感性分析中均相关,但为观察性关联,不能解释为因果。
  • 缺乏组织学确认限制了对肿瘤学安全性的结论。

研究设计与样本

  • 回顾性队列研究,设置于土耳其安卡拉的三级转诊中心。
  • 纳入2021年1月至2026年1月期间18-45岁接受经阴道超声引导EST的卵巢子宫内膜异位囊肿女性。
  • 共筛查115次EST尝试,112次技术成功;主要研究队列91例,88例可进行时间-事件分析。
  • 采用标准化10步经阴道EST技术:抽吸、盐水冲洗、注入96-96.5%乙醇(为抽吸体积的60%,最大100 mL)、保留10分钟、完全抽吸。

主要发现

  • 复发/持续存在定义为初始EST后超声检出≥20 mm的子宫内膜异位囊肿样囊肿;单独重复干预不作为复发标准。
  • 88例可评估患者中22例(25.0%)发生复发/持续存在;Kaplan-Meier累积估计12个月为22.3%,24个月为29.1%。
  • 单变量分析中较高BMI与复发/持续存在相关(HR 1.21每1 kg/m;95%CI 1.10-1.33;P<0.001)。
  • 主要多变量模型中BMI的HR为1.20(95%CI 1.10-1.32;P<0.001);扩展敏感性模型中调整HR为1.22(95%CI 1.11-1.35;P<0.001)。
  • 技术成功率为97.4%(112/115;95%CI 92.6%-99.5%);围手术期并发症8/91(8.8%;95%CI 3.9%-16.6%);无Clavien-Dindo IIIb-V级并发症(0/91;95%CI 0.0%-4.0%)。

关键数值与推荐

  • 复发/持续存在:初始EST后超声检出≥20 mm的子宫内膜异位囊肿样囊肿。
  • 技术成功率97.4%(112/115;95%CI 92.6%-99.5%)。
  • 围手术期并发症发生率8.8%(8/91;95%CI 3.9%-16.6%)。
  • 无Clavien-Dindo IIIb-V级并发症(0/91;95%CI 0.0%-4.0%)。
  • BMI与复发/持续存在的多变量HR为1.20(95%CI 1.10-1.32;P<0.001)。

临床怎么用

  • EST可作为经过选择患者的微创治疗选择,技术成功率高且严重并发症风险低。
  • 对较高BMI患者应告知复发/持续存在风险可能增加,并加强术后超声随访。
  • 术后应关注卵巢储备,AMH在1个月和6个月出现小幅但统计学显著的下降。

局限性

  • 观察性关联不能解释为因果。
  • 缺乏组织学确认,限制了对肿瘤学安全性的结论。
  • 回顾性设计及单中心设置可能影响普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To evaluate recurrence/persistence after the initial transvaginal ultrasound-guided ethanol sclerotherapy (EST) for ovarian endometriomas, identify recurrence-associated factors, and assess feasibility, safety, and ovarian reserve outcomes after the initial procedure. DESIGN: Retrospective cohort study. SETTING: Tertiary referral center, Ankara, Türkiye. PATIENTS: Women aged 18-45 years undergoing transvaginal ultrasound-guided EST for ovarian endometriomas between January 2021 and January 2026. A total of 115 EST attempts were screened; 112 were technically successful. The primary study cohort included 91 patients; time-to-event analysis was available for 88 patients. INTERVENTIONS: A standardized 10-step transvaginal EST technique was used: aspiration, saline irrigation, instillation of 96-96.5% ethanol at 60% of aspirated volume (maximum 100 mL), 10-minute retention, and complete aspiration. MEASUREMENTS AND MAIN RESULTS: Recurrence/persistence was defined as ultrasonographic detection of an endometrioma-like cyst ≥20 mm after the initial EST; repeat intervention alone was not a recurrence criterion. Recurrence/persistence occurred in 22 of 88 evaluable patients (25.0%); Kaplan-Meier cumulative estimates were 22.3% at 12 months and 29.1% at 24 months. Higher BMI was associated with recurrence/persistence in univariable analysis (HR, 1.21 per 1 kg/m; 95% CI, 1.10-1.33; P<0.001) and in the primary multivariable model (HR, 1.20; 95% CI, 1.10-1.32; P<0.001). In an expanded sensitivity model, the adjusted HR for BMI was 1.22 (95% CI, 1.11-1.35; P<0.001). Technical success was 97.4% (112/115; 95% CI, 92.6%-99.5%). Periprocedural complications occurred in 8 of 91 patients (8.8%; 95% CI, 3.9%-16.6%); no Clavien-Dindo grade IIIb-V complications occurred (0/91; 95% CI, 0.0%-4.0%). Median AMH declined modestly at 1 month (-0.16 ng/mL; P<0.001) and 6 months (-0.12 ng/mL; P=0.019). CONCLUSION: EST achieved high technical success in this carefully selected cohort. Recurrence/persistence remained clinically relevant, and higher BMI was associated with recurrence/persistence across primary and sensitivity analyses. This observational association should not be interpreted as causal, and the absence of histological confirmation limits conclusions regarding oncologic safety.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Aslan B, Kaplan NB, Atabekoğlu C, et al. Risk Factors for Recurrence and Safety Outcomes After Ethanol Sclerotherapy for Ovarian Endometriomas. J Minim Invasive Gynecol. 2026. PMID: 42830121. doi:10.1016/j.jmig.2026.09.471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。